BMC Cancer最新文献

{"title":"Pancreatic cancer mortality in China from 2004 to 2021: an in-depth analysis of age, gender, and regional disparities.","authors":"Rui He, Zhengnan Shen, Qiuping Chen, Haiyang Hu, Xin Ding, Zhenglong Zheng, Quansheng Feng, Baixue Li","doi":"10.1186/s12885-025-13863-0","DOIUrl":"10.1186/s12885-025-13863-0","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to analyze the trends and epidemiological characteristics of pancreatic cancer (PC) mortality in China from 2004 to 2021, focusing on gender, age, and regional disparities. The goal was to provide a comprehensive understanding of PC mortality and identify key risk factors to support future prevention and control strategies.</p><p><strong>Methods: </strong>Using data from the national Disease Surveillance Point (DSP) system, which covers a large and representative sample of the Chinese population, the study examined pancreatic cancer mortality trends across different age groups, sexes, and regions. Statistical analyses, including the independent-sample t-test and age-period-cohort (APC) model, were employed to assess mortality differences and annual percentage changes from 2004 to 2021.</p><p><strong>Results: </strong>The study recorded a significant increase in pancreatic cancer mortality, particularly among males and older adults. Mortality was consistently higher in urban areas, but the growth rate in rural areas surpassed that of urban areas. Regional disparities were also observed, with the eastern region showing the highest mortality rates but slower increases compared to the central and western regions. Key risk factors, including aging, diabetes, smoking, and chronic pancreatitis, were identified, with gender-specific differences linked to lifestyle factors such as smoking and alcohol consumption.</p><p><strong>Conclusion: </strong>Pancreatic cancer mortality in China has shown significant increases over the past 18 years, especially among males, older adults, and rural populations. The findings highlight the urgent need for targeted public health interventions to address gender- and age-specific risks, as well as healthcare access inequalities in less developed regions. Future research should focus on gathering more granular, individual-level data to better understand the complex interplay of risk factors and inform more effective prevention and treatment strategies.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"891"},"PeriodicalIF":3.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV integration status conversion and CIN2 + cancer risk stratification based on HPV integration levels among HPV integration-positive women: a 1-year follow-up study.","authors":"Kexin Li, Fanwei Huang, Tao Zhang, Fan Yang, Weitao Duan, Shimin Chen, Ting Hu, Xiaoyuan Huang","doi":"10.1186/s12885-025-14138-4","DOIUrl":"10.1186/s12885-025-14138-4","url":null,"abstract":"<p><strong>Background: </strong>HPV integration is a crucial genetic step in cervical carcinogenesis and the level of HPV integration increases with the grade of precancerous lesion. This study aimed to conduct risk stratification based on HPV integration levels and HPV integration status conversion among HPV integration-positive women after 1 year of follow-up.</p><p><strong>Methods: </strong>This prospective cohort study was conducted in Tongji Hospital between June 2020 and August 2022 and included 1297 consecutive HPV-positive women. The level of integration reads was stratified for risk assessment.</p><p><strong>Results: </strong>In total, 194 women were HPV integration-positive and followed for at least 1 year. The immediate risk of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) increased from 36.2% (25/69) among women with 6-20 integration reads to 93.8% (30/32) among women with more than 1000 integration reads (P_trend < 0.001). The 1-year cumulative risk of CIN2 + increased from 39.1% (27/69) among women with 6-20 integration reads to 96.9% (31/32) among women with more than 1000 integration reads (P_trend < 0.001). The 1-year cumulative risk of CIN2 + with HPV integration reads more than 40 was 93.8% (90/96), which was significantly higher than that of HPV integration reads less than 40 (38/85, P < 0.001). Among women with HPV integration reads more than 40, 99.0% (95/96) of women progressed with positive outcomes after one year of follow-up (persistent integration at the same site, immediate CIN2+, and 1-year CIN2+). The progression rate of women with persistent integration at the same site was 41.6% (5/12), which was significantly higher than those of HPV integration-negative conversion (0/41, 0%, P < 0.001).</p><p><strong>Conclusion: </strong>The number of HPV integration reads may help CIN2 + risk stratification and facilitate the clinical management of high-risk patients.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"885"},"PeriodicalIF":3.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating single-cell and bulk RNA profiles to uncover glutamine metabolism's role in prognosis and immune dynamics in multiple myeloma.","authors":"Fei Zhao, Feifei Che","doi":"10.1186/s12885-025-14239-0","DOIUrl":"10.1186/s12885-025-14239-0","url":null,"abstract":"<p><strong>Objective: </strong>Multiple myeloma (MM) exhibits significant heterogeneity, leading to variable treatment responses and poor clinical outcomes. Glutamine metabolism-related genes (GMRGs) represent critical regulators of tumor biology, yet their prognostic and therapeutic significance in MM remains unexplored. This study aims to identify GMRG-driven tumor signatures and establish their clinical utility as prognostic biomarkers, therapeutic targets and enhancers of drug sensitivity.</p><p><strong>Methods: </strong>Integrated transcriptomic and single-cell sequencing analyses of public multi-omics cohorts enabled systematic identification of GMRGs in MM through weighted co-expression network analysis coupled with univariate Cox proportional hazards modeling. Clinically prioritized GMRGs showing elevated expression in patient specimens were functionally validated through proliferation assays and pharmacological sensitivity profiling.</p><p><strong>Results: </strong>Integrated multi-omics analysis combining single-cell sequencing with bulk transcriptomic profiling and prognostic screening identified 51 prognostic GMRGs, with 10 core signature genes selected for model construction. The risk stratification system demonstrated robust prognostic capacity validated across multiple independent MM cohorts. Pathway enrichment revealed significant involvement in immune system, cell cycle and tumor signaling. MM patient validation identified DLD, SFT2D2, and UBA2 as significantly upregulated genes that promote tumor growth through enhancement of proliferation. Mechanistic investigations via shRNA-mediated knockdown established that DLD and UBA2 silencing significantly enhanced therapeutic efficacy of MM inhibitors.</p><p><strong>Conclusion: </strong>Multicohort-validated GMRGs (DLD/UBA2) drive MM progression and MM inhibitor responses. Clinical upregulation and functional silencing confirm dual therapeutic potential as prognostic biomarkers and drug-sensitizing targets.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"887"},"PeriodicalIF":3.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis.","authors":"Yun Liu, Ying Zhang, Jinhong Gao, Lijuan Wang, Fang Xie, Chengtao Zhang, Peimin Mao, Jinsong Yan","doi":"10.1186/s12885-025-14311-9","DOIUrl":"10.1186/s12885-025-14311-9","url":null,"abstract":"<p><strong>Background: </strong>Venetoclax with hypomethylating agents (VEN-HMAs) has shown inconsistent efficacy versus induction chemotherapy (IC) in newly diagnosed AML (ND-AML). Whether or not VEN-HMAs are of clinical benefit remains uncertain. We conducted this meta-analysis to evaluate the clinical benefit of VEN-HMAs versus IC in various subtypes of ND-AML.</p><p><strong>Methods: </strong>We searched PubMed, Embase, Cochrane Library, and Web of Science databases up to 17 June 2024. The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). Data were extracted to perform meta-analysis or descriptive analysis. The random-effects model was used to calculate the effect sizes and 95% confidence interval (CI). Relative risk (RR) was used to estimate complete response (CR), CR/ complete response with incomplete blood count recovery (CRi), overall response rate (ORR), and 30-day mortality. Hazard ratio (HR) was used to evaluate overall survival (OS) data.</p><p><strong>Results: </strong>Fifteen retrospective cohort studies with 3809 participants were identified. Compared to the IC group, the pooled RR estimates for VEN-HMAs were 1.05 (95% CI 0.88-1.26, P = 0.591) for CR, 1.09 (95% CI 0.96-1.23, P = 0.195) for CR/ CRi, 0.84 (95% CI 0.60-1.18, P = 0.318) for ORR, and 0.86 (95% CI 0.50-1.49; P = 0.596) for 30-day mortality. VEN-HMAs prolonged the OS advantage in the ND-AML population (HR = 0.80, 95% CI 0.66-0.97, P = 0.025), and was demonstrated in patients with nucleophosmin 1 (NPM1) mutation (HR = 0.64, 95% CI 0.44-0.92, P = 0.017). In AML patients with RUNX1::RUNX1T1 cytogenetic abnormalities, the pooled ORR was lower in the VEN-HMAs group (RR = 0.44, 95% CI 0.28-0.69, P < 0.001), but OS was of no significantly different (HR = 1.30, 95% CI 0.52-3.26,P = 0.58). However, only 2 studies were available and the results should be taken with caution. OS benefit was similar in other subgroup analyses based on cytogenetic risk, age, and AML type (de novo, secondary, treatment-related or prior therapy for myeloid disease cohort).</p><p><strong>Conclusion: </strong>Compared with the IC group, VEN-HMAs improved OS in ND-AML, especially in the NPM1 mutation subgroup (HR = 0.64), ensured the efficacy of CR, CR/CRi and ORR, without increasing 30-day mortality, necessitating further head-to-head randomized controlled trials (RCTs).</p><p><strong>Trial registration: </strong>This trial was registered with PROSPERO ( www.crd.york.ac.uk/prospero/ ) on 13 July 2024, the registration number is CRD42024560585.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"894"},"PeriodicalIF":3.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between MYCN gene polymorphisms and neuroblastoma susceptibility: a case-control study in Chinese children from Jiangsu Province.","authors":"Jiabin Liu, Mengzhen Zhang, Yu Ouyang, Jiaming Chang, Wenli Zhang, Chunlei Zhou, Jing He, Xinxin Zhang","doi":"10.1186/s12885-025-14310-w","DOIUrl":"10.1186/s12885-025-14310-w","url":null,"abstract":"<p><strong>Background: </strong>Neuroblastoma, developed from the sympathetic nervous system, is a deadly childhood malignancy. There is an urgent need to elucidate its intricated etiology. MYCN amplification leads to aggressive neuroblastoma and represents a powerful marker of poor prognosis. However, the correlation between MYCN gene polymorphisms and neuroblastoma susceptibility remains largely unknown in Chinese Han children.</p><p><strong>Methods: </strong>We conducted a case-control study to evaluate the associations between MYCN gene polymorphisms and neuroblastoma susceptibility, involving 402 cases and 473 controls from Jiangsu Province, China. The association strength between the studied polymorphisms and neuroblastoma susceptibility was quantified using odds ratios and 95% confidence intervals.</p><p><strong>Results: </strong>Four studied polymorphisms (rs57961569 G > A, rs9653226 T > C, rs13034994 A > G, and rs60226897 G > A) were significantly associated with neuroblastoma susceptibility. Stratified analysis of two polymorphisms (rs13034994 A > G and rs60226897 G > A) demonstrated stronger associations with neuroblastoma susceptibility in specific subgroups. Moreover, survival analysis demonstrated elevated MYCN expression in high-risk patients, with reduced expression correlating to improved survival outcomes.</p><p><strong>Conclusion: </strong>Our study indicated that MYCN gene polymorphisms are significantly associated with neuroblastoma susceptibility in the eastern Chinese population and that high expression of the MYCN gene may suggest a poor prognosis. Nevertheless, further verification should be conducted with large-scale and well-designed studies to confirm our findings.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"892"},"PeriodicalIF":3.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of breast cancer surgery on levels of depression and anxiety: a systematic review and meta-analysis.","authors":"Fatemeh Movahed, Masoud Dehbozorgi, Saba Goodarzi, Fatemeh Esmaeilpur Abianeh, Razman Arabzadeh Bahri, Arman Shafiee","doi":"10.1186/s12885-025-14277-8","DOIUrl":"10.1186/s12885-025-14277-8","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer surgery is a critical intervention with potentially significant psychological impacts. This systematic review and meta-analysis investigate the effect of different surgical approaches on levels of depression and anxiety in breast cancer patients.</p><p><strong>Methods: </strong>Following the PRISMA 2020 guidelines, we conducted a comprehensive search of international bibliometric databases including PubMed, Scopus, Web of Science, and Embase, up to March 21, 2024.</p><p><strong>Results: </strong>From 1576 identified articles, 13 studies were included after screening and eligibility assessments. Meta-analysis results indicated a significant reduction in depression (SMD: -0.14; 95% CI: -0.25 to -0.02) and anxiety (SMD: -0.42; 95% CI: -0.56 to -0.28) following breast cancer surgery. Subgroup analysis revealed that mastectomy patients experienced a notable decrease in both depression and anxiety, while results for breast-conserving surgery and reconstruction were more varied.</p><p><strong>Conclusions: </strong>Breast cancer surgery is associated with a decrease in depression and anxiety, particularly following mastectomy. Further research should focus on long-term psychological effects and the development of tailored interventions for different surgical types.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"889"},"PeriodicalIF":3.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction models of breast cancer molecular subtypes based on multimodal ultrasound and clinical features.","authors":"Hui Li, Chang-Tao Zhang, Hua-Guo Shao, Lin Pan, Zhongyun Li, Min Wang, Shi-Hao Xu","doi":"10.1186/s12885-025-14233-6","DOIUrl":"10.1186/s12885-025-14233-6","url":null,"abstract":"<p><strong>Background and aims: </strong>Breast cancer classify into four molecular subtypes: Luminal A, Luminal B, HER2-overexpressing (HER2), and triple-negative (TNBC) based on immunohistochemical assessments. The multimodal ultrasound features correlate with biological biomarkers and molecular subtypes, facilitating personalized, precision-guided treatment strategies for patients. In this study, we aimed to explore the differences of multimodal ultrasound features generated from conventional ultrasound (CUS), shear wave elastography (SWE) and contrast-enhanced ultrasound (CEUS) between molecular subtypes of breast cancer, investigate the value of prediction model of breast cancer molecular subtypes based on multimodal ultrasound and clinical features.</p><p><strong>Methods: </strong>Breast cancer patients who visited our hospital from January 2023 to June 2024 and underwent CUS, SWE and CEUS were selected, according to inclusion criteria. Based on the selected effective feature subset, binary prediction models of features of CUS, features of SWE, features of CEUS and full parameters were constructed separately for the four breast cancer subtypes Luminal A, Luminal B, HER2, and TNBC, respectively.</p><p><strong>Results: </strong>There were ten parameters that showed significant differences between molecular subtypes of breast cancer, including BI-RADS, palpable mass, aspect ratio, maximum diameter, calcification, heterogeneous echogenicity, irregular shape, standard deviation elastic modulus value of lesion, time of appearance, peak intensity. Full parameter models had highest area under the curve (AUC) values in every test set. In aggregate, judging from the values of accuracy, precision, recall, F1 score and AUC, models used features selected from full parameters showed better prediction results than those used features selected from CUS, SWE and CEUS alone (AUC: Luminal A, 0.81; Luminal B, 0.74; HER2, 0.89; TNBC, 0.78).</p><p><strong>Conclusions: </strong>In conclusion, multimodal ultrasound features had differences between molecular subtypes of breast cancer and models based on multimodal ultrasound data facilitated the prediction of molecular subtypes.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"886"},"PeriodicalIF":3.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging roles of ADAM6 and PRSS1 as novel diagnostic/prognostic biomarkers for acute lymphoblastic and myeloid leukemia in adults.","authors":"Heba M Anis, Nahed M Rakha, Dina H Kassem, Amany M Kamal","doi":"10.1186/s12885-025-14292-9","DOIUrl":"10.1186/s12885-025-14292-9","url":null,"abstract":"<p><strong>Background: </strong>Acute leukemia is an aggressive, highly heterogeneous hematological malignancy. A Disintegrin And Metalloproteinase Domain-6 (ADAM6), a member of ADAMs family, has emerged recently as a potential novel player in pediatric acute lymphoblastic leukemia (ALL), and its function remains largely elusive. Serine Protease-1 (PRSS1) is another emerging molecular mediator in cancer development. However, its role in acute leukemia has not been adequately studied. Interestingly, ADAM6 and PRSS1 were identified among the genes with the highest percentage of chromosomal changes in profiled B-cell precursor ALL patients. Both are emerging novel mediators of extracellular matrix (ECM) remodeling. Thus, this study was designed to investigate the roles of ADAM6 and PRSS1 in ALL and acute myeloid leukemia (AML) in adults.</p><p><strong>Methods: </strong>Adult patients with de novo ALL (n = 36), de novo AML (n = 40), and healthy control subjects (n = 55) were enrolled in this study. Circulating serum levels of ADAM6 and PRSS1 were measured by ELISA technique.</p><p><strong>Results: </strong>Serum levels of ADAM6 were significantly higher in ALL and AML patients compared to healthy control subjects (208.7(178.3-337.3), 186.4(155.3-479.6), and 78.6(55.8-101.8) pg/ml, p < 0.0001), respectively. Whereas, serum levels of PRSS1 were found to be significantly lower in ALL and AML patients compared to healthy controls (175.1(153.7-232.2), 177.9(145.3-206.4), and 247.5(204.3-375.3) ng/ml, p < 0.0001), respectively. Both ADAM6 and PRSS1 exhibited a very good diagnostic potential by ROC analyses. ADAM6 levels significantly varied between CD22⁺/CD22^- and CD45⁺/CD45^-, while PRSS1 levels significantly varied between HLA-DR⁺/HLA-DR^- ALL patients, suggesting their prognostic implications. Also, ADAM6 and PRSS1 were found to be significantly correlated with each other.</p><p><strong>Conclusion: </strong>The results of the current study portray ADAM6 and PRSS1 as new potential diagnostic/prognostic biomarkers and potential therapeutic targets in adult acute leukemia patients, and shed light on their role as novel interrelated mediators possibly implicated in tumor micro-environment remodeling.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"884"},"PeriodicalIF":3.4,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"E2F2(E2F transcription factor 2) as a potential therapeutic target in meibomian gland carcinoma: evidence from functional and epigenetic studies.","authors":"Wei Wang, Hetong Wang, Xun Liu, Fei Xu, Qin Tang, Chuanli Zhang, Jiaqi Lin, Limin Zhu, Tingting Lin","doi":"10.1186/s12885-025-13833-6","DOIUrl":"10.1186/s12885-025-13833-6","url":null,"abstract":"<p><strong>Background: </strong>Meibomian Gland Carcinoma (MGC) is a highly malignant eyelid tumor with a poor prognosis. This study investigates the molecular mechanisms underlying MGC, focusing on the abnormal expression of E2F transcription factor 2 (E2F2), often observed in tumors and potentially linked to DNA methylation.</p><p><strong>Methods: </strong>E2F2 expression was measured in MGC cells and tissues. Tissue samples from 3 normal meibomian glands (MG) and 36 MGC patients were used to construct a tissue microarray. Functional assays were performed by modifying E2F2 expression, including CCK8, wound healing, Transwell, and analysis of epithelial-mesenchymal transition (EMT)-related markers. Flow cytometry was used to assess cell apoptosis and cell cycle. RNA sequencing was conducted to identify differential genes after treating MGC cells with the methylation inhibitor 5-aza-2'-deoxycytidine (5-aza-2-dc), to explore the relationship between E2F2 downregulation in MGC and methylation.</p><p><strong>Results: </strong>E2F2 expression was significantly lower in MGC cells compared to normal MG cells. Immunohistochemical analysis showed low E2F2 expression in MGC. Specifically, immunohistochemical staining results have revealed a negative correlation trend between E2F2 and Ki-67 expression, as well as a positive correlation trend between E2F2 and P21, P27 expression. E2F2 knockdown increased MGC cell proliferation, migration, and invasion. Flow cytometry revealed that E2F2 knockdown reduced apoptosis, decreased the G0/G1 phase, and increased the S phase, while E2F2 overexpression produced opposite effects. RNA sequencing revealed that a total of 87 genes were differentially expressed in the 5-aza-2-dc experimental group compared to the control group, with 72 mRNAs showing upregulated expression and 15 mRNAs showing downregulated expression. Bioinformatics analysis results indicated that the functions of these differentially expressed genes were concentrated, and the biological processes mainly involved DNA replication, among others. The signaling pathways associated with these genes primarily included DNA replication and the cell cycle. RNA sequencing identified differential gene expression after methylation inhibition in MGC cells with 5-aza-2-dc, demonstrating that demethylation significantly upregulated E2F2. MSP assays confirmed reduced methylation levels. Additionally, inhibiting gene methylation in MGC cells suppressed proliferation, migration, and invasion.</p><p><strong>Conclusion: </strong>E2F2 presents a promising therapeutic target for MGC. Overexpression of E2F2 and methylation inhibition in MGC cells may reverse E2F2 gene silencing, inhibiting malignant progression. These findings provide new perspectives for targeted therapies and precise, individualized treatment in MGC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"880"},"PeriodicalIF":3.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of intra-hepatectomy ICGR15 of the remnant liver for post-hepatectomy liver failure in hemi-hepatectomy: a prospective study.","authors":"Tianyi Liang, Yongfei He, Shutian Mo, Yuan Liao, Ketuan Huang, Qiang Gao, Xiaoqiang Shen, Chengkun Yang, Xiwen Liao, Wei Qin, Guangzhi Zhu, Hao Su, Xinping Ye, Chuangye Han, Tao Peng","doi":"10.1186/s12885-025-14296-5","DOIUrl":"10.1186/s12885-025-14296-5","url":null,"abstract":"<p><strong>Background and objective: </strong>Post-hepatectomy liver failure (PHLF) is one of the major complications following hepatectomy for hepatocellular carcinoma (HCC). Early identification and precise prediction of PHLF are essential for effective management. This study aimed to evaluate the predictive value of intra-hepatectomy indocyanine green retention rate at 15 min (ICGR15) for the remnant liver for grade B/C PHLF in HCC patients undergoing hemi-hepatectomy.</p><p><strong>Methods: </strong>This prospective study recruited 31 HCC patients who underwent hemi-hepatectomy. ICGR15 was measured at three time points: pre-hepatectomy, intra-hepatectomy (for the remnant liver), and post-hepatectomy. The primary endpoint was the occurrence of grade B/C PHLF according to ISGLS criteria. Logistic regression analysis was employed to evaluate the predictive performance of each parameter and to conduct risk assessment. The XGBoost algorithm was utilized to compare the predictive values of various parameters by calculating the mean Shap values.</p><p><strong>Results: </strong>Among the study participants, 25.8% (8 patients) developed grade B/C PHLF. The intra-hepatectomy ICGR15 for remnant liver exhibited the highest predictive accuracy for grade B/C PHLF, with a ROC-AUC of 0.864 and a PR-AUC of 0.791. The optimal threshold for ICGR15-intra was established at 19.8%. Patients with ICGR15-intra value of 19.8% or higher were found at significantly increased risk of grade B/C PHLF (OR[95% CI] = 3.602[1.437-6.750], P value = 0.004), and experienced a higher incidence of severe post-hepatectomy complications.</p><p><strong>Conclusion: </strong>Intra-hepatectomy ICGR15 for the remnant liver was an important predictor of grade B/C PHLF in patients undergoing hemi-hepatectomy for HCC. An intra-hepatectomy ICGR15 threshold of 19.8% might effectively identify patients at high risk of developing grade B/C PHLF and severe post-hepatectomy complications, helping surgeons' final decision-making on the table.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"881"},"PeriodicalIF":3.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}